Baron Philippe Vlerick increases shareholding in ThromboGenics NV to 6.4%
(Thomson Reuters ONE) -
Regulated Information - Transparency Statement
Leuven, Belgium, 10 September 2015 - Pursuant to Belgian transparency
legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR)
received a transparency notification on 9 September 2015 from Philippe Vlerick
and controlled entities.
Philippe Vlerick (Bareldam SA) notified that on 9 September 2015, 2,324,719
shares, representing 6.44% of the current 36,094,349 outstanding ThromboGenics
shares, were held by himself and controlled entities.
On September 9, 2015, based on all received transparency declarations received,
ThromboGenics NV is aware of the following participations:
+--------------------------------------+--------------------+------------------+
| Shareholder |number of securities|% of voting rights|
+--------------------------------------+--------------------+------------------+
|Mr Landon T. Clay and all entities| | |
|controlled by him | | |
| |1,071,061 |2.97% |
+--------------------------------------+--------------------+------------------+
|Mr Thomas M. Clay and all entities| | |
|controlled by him | | |
| |2,790,062 |7.73% |
+--------------------------------------+--------------------+------------------+
|Norges Bank |1,065,605 |2.95% |
+--------------------------------------+--------------------+------------------+
|Philippe Vlerick and all entities|2,324,719 |6.44% |
|controlled by him | | |
+--------------------------------------+--------------------+------------------+
In May, Baron Philippe Vlerick was appointed as a non-executive member of the
Board of ThromboGenics NV at an extraordinary shareholders' assembly that took
place on August 20th.
Philippe Vlerick is the owner, Chairman and CEO of several businesses in Belgium
and abroad. He currently serves as the Chairman and Chief Executive Officer of
Vlerick Group (Belgium). He also serves as the Chairman and CEO of UCO Textiles
NV. In addition, he is the Vice-chairman of KBC Group, Corelio, smartphoto Group
and Durabilis. Baron Vlerick is also a member of the Board of Directors of
Exmar, Hamon & Cie, Besix Group and I.V.C. (Belgium).
Mr Vlerick holds a Degree in Philosophy and Law from the University of Leuven,
and an MBA General Management degree (PUB) (Ghent, Vlerick School of Management
- 1979). He also holds a Master's degree in Business Administration from Indiana
University, Bloomington (USA - 1980).
He was elected 2006 Manager of the Year by Trends, a leading business magazine
in Belgium. He was granted the title of Baron in 2008, and became Commander of
the Order of Leopold in 2013.
END
For further information please contact:
+------------------------------------------+-----------------------------------+
|ThromboGenics |Citigate Dewe Rogerson |
| | |
| | |
| | |
|Wouter Piepers, |David Dible/Malcolm Robertson |
| | |
|Global Head of Corporate Communications &|Tel: +44 20 7282 2867 |
|IR | |
| |Malcolm.robertson(at)citigatedr.co.uk |
|+32 16 75 13 10 / +32 478 33 56 32 | |
| | |
|wouter.piepers(at)thrombogenics.com | |
| | |
| | |
+------------------------------------------+-----------------------------------+
About ThromboGenics
ThromboGenics is an integrated biopharmaceutical company focused on developing
and commercializing innovative treatments for diabetic eye disease.
The Company's first product, JETREA(® )(ocriplasmin), has been approved in 53
countries across the globe. In the US, ThromboGenics is commercializing JETREA(®
)via its subsidiary ThromboGenics inc. ThromboGenics signed an agreement with
Alcon, a division of Novartis, for the commercialization of JETREA(®) outside
the United States.
ThromboGenics is planning a Phase II clinical trial with JETREA(® )in diabetic
retinopathy. Next to JETREA(®), the company is in the midst of evaluating a
number of potential candidates for next generation treatments in diabetic eye
disease.
ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ
(US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels
exchange under the symbol THR. More information is available at
www.thrombogenics.com.
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained in
the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction. No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: ThromboGenics NV via GlobeNewswire
[HUG#1951178]
Unternehmensinformation / Kurzprofil:
Datum: 10.09.2015 - 17:55 Uhr
Sprache: Deutsch
News-ID 419351
Anzahl Zeichen: 8008
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 198 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Baron Philippe Vlerick increases shareholding in ThromboGenics NV to 6.4%"
steht unter der journalistisch-redaktionellen Verantwortung von
ThromboGenics NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
